Short answer
Maze Therapeutics, Inc. (MAZE) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for quarter ended September 30, 2026.
Maze Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Full results and management commentary available in Exhibit 99.1 press release
- Investor focus: cash runway, R&D spending, pipeline progress, and any updated guidance
Item EX-99.1 · Exhibit EX-99.1
- Q3 net loss widened to $48.0M, or $0.79 per share, from $30.1M, reflecting accelerated clinical investment
- Cash, equivalents and marketable securities reached $477.0M, supporting projected operations into 2029
- MZE829 HORIZON enrollment exceeded target with more than 50 patients; complete data expected early 2027
- MZE829 pivotal trial planned for H1 2027, subject to regulatory feedback, creating a near-term development catalyst
- MZE782 PKU enrollment continues, with topline data expected in 2027 and CKD Phase 2 initiation targeted for H1 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Maze Therapeutics, Inc. 8-K filings
Get the next MAZE 8-K as it lands
Follow MAZE for push alerts, or ask the research agent what this filing means.